Watchlist Price Alert

Veracyte Inc. (VCYT)

NASDAQ: VCYT · Real-Time Price · USD

31.19

0.35 (1.13%)

At close: May 08, 2025, 3:59 PM

1.13% (1D)

Bid	32.74
Market Cap	2.44B
Revenue (ttm)	445.76M
Net Income (ttm)	24.14M
EPS (ttm)	0.31
PE Ratio (ttm)	100.61
Forward PE	43.96
Analyst	Buy

Ask	32.74
Volume	1,892,755
Avg. Volume (20D)	1,020,780
Open	30.12
Previous Close	30.84
Day's Range	27.24 - 31.57
52-Week Range	19.73 - 47.32
Beta	2.15

About VCYT

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol VCYT

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for VCYT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Veracyte has released their quartely earnings on May 7, 2025:

Revenue of $114.47M exceeds estimates by $3.74M, with 18.20% YoY growth.

EPS of 0.31 exceeds estimates by 0.11, with 63.16% YoY growth.

Why Price Moved

2 months ago

+0.46%

Veracyte shares are trading lower. The company rep... Unlock content with Pro Subscription

6 months ago

+2.05%

Veracyte shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 sales guidance. Needham and UBS maintained Buy ratings and raised their respective price targets on the stock.

News

1 day ago · zacks.com

What Makes Veracyte (VCYT) a New Buy Stock

Veracyte (VCYT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 day ago · seekingalpha.com

Veracyte, Inc. (VCYT) Q1 2025 Earnings Call Transcript

Veracyte, Inc. (NASDAQ:VCYT ) Q1 2025 Earnings Call May 7, 2025 4:30 PM ET Company Participants Shayla Gorman - Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Finan...

2 days ago · zacks.com

Veracyte (VCYT) Q1 Earnings and Revenues Beat Estimates

Veracyte (VCYT) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.02 per share a year ago.

2 weeks ago · businesswire.com

Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer.

2 weeks ago · businesswire.com

Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing Will Be Presented at AUA Annual Meeting.

2 weeks ago · businesswire.com

Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database Release

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to National Cancer Institute's SEER Specialized Database Release.

3 weeks ago · zacks.com

Should You Continue to Hold Veracyte Stock in Your Portfolio?

Strength in the Afirma and Decipher franchises continues to bode well for VCYT stock.

3 weeks ago · zacks.com

Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

3 weeks ago · zacks.com

Here's Why Veracyte (VCYT) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

4 weeks ago · zacks.com

Veracyte (VCYT) Just Overtook the 20-Day Moving Average

After reaching an important support level, Veracyte (VCYT) could be a good stock pick from a technical perspective. VCYT surpassed resistance at the 20-day moving average, suggesting a short-term bull...

Load More News